Peringatan Keamanan

The onset of impairment of consciousness is relatively rapid in benzodiazepine poisoning. Onset is more rapid following larger doses and with agents of shorter duration of action. The most common and initial symptom is somnolence. This may progress to coma Grade I or Grade II following very large ingestions.

Cinolazepam

DB01594

small molecule experimental

Deskripsi

Cinolazepam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. It is not approved in Canada or America.

Struktur Molekul 2D

Berat 357.766
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 9 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Bioavailability following oral administration is 90-100%.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol.
  • 2. Limit caffeine intake.
  • 3. Take with food.

Interaksi Obat

714 Data
Buprenorphine Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Hydrocodone Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Magnesium sulfate The therapeutic efficacy of Cinolazepam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Cinolazepam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Mirtazapine Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Orphenadrine Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Pramipexole Cinolazepam may increase the sedative activities of Pramipexole.
Ropinirole Cinolazepam may increase the sedative activities of Ropinirole.
Rotigotine Cinolazepam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Cinolazepam.
Suvorexant Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Thalidomide Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Clozapine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Clozapine.
Methadone Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Cinolazepam.
Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Cinolazepam.
Sodium oxybate Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Teduglutide The serum concentration of Cinolazepam can be increased when it is combined with Teduglutide.
Flumazenil Flumazenil may decrease the sedative activities of Cinolazepam.
Ethanol Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Cinolazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cinolazepam.
Fluvoxamine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Cinolazepam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Cinolazepam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Cinolazepam is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Cinolazepam is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Cinolazepam is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Cinolazepam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Cinolazepam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Cinolazepam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Cinolazepam is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Cinolazepam.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Cinolazepam.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Cinolazepam.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Cinolazepam.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Cinolazepam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Cinolazepam.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Cinolazepam.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Cinolazepam.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Cinolazepam.
Pizotifen The risk or severity of CNS depression can be increased when Cinolazepam is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Cinolazepam is combined with Dosulepin.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Cinolazepam.
Zopiclone The risk or severity of adverse effects can be increased when Cinolazepam is combined with Zopiclone.
Caffeine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Caffeine.
Theophylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Theophylline.
Dyphylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Dyphylline.
Pentoxifylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Pentoxifylline.
Mercaptopurine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Mercaptopurine.
Aminophylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Aminophylline.
Oxtriphylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Oxtriphylline.
Theobromine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Theobromine.
Fenethylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Fenethylline.
8-azaguanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 8-azaguanine.
7,9-Dimethylguanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 7,9-Dimethylguanine.
Xanthine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Xanthine.
7-Deazaguanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 7-Deazaguanine.
Guanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Guanine.
9-Methylguanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 9-Methylguanine.
Peldesine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Peldesine.
Hypoxanthine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Hypoxanthine.
9-Deazaguanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 9-Deazaguanine.
Propentofylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Propentofylline.
Valomaciclovir The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Valomaciclovir.
3-isobutyl-1-methyl-7H-xanthine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
Uric acid The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Uric acid.
Doxofylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Doxofylline.
6-O-benzylguanine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 6-O-benzylguanine.
Lisofylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Lisofylline.
Lobucavir The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Lobucavir.
Cafedrine The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Cafedrine.
Theodrenaline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Theodrenaline.
Bamifylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Bamifylline.
Proxyphylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Proxyphylline.
Acefylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Acefylline.
Etamiphylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Etamiphylline.
Pentifylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Pentifylline.
Bufylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Bufylline.
Bromotheophylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Bromotheophylline.
Furafylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with Furafylline.
8-chlorotheophylline The therapeutic efficacy of Cinolazepam can be decreased when used in combination with 8-chlorotheophylline.

Target Protein

Translocator protein TSPO
GABA(A) Receptor GABRA1
GABA(A) Receptor Benzodiazepine Binding Site GABRA1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Gerodorm

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul